- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04530227
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
A Pilot Study of Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This trial will evaluate the safety and efficacy of camrelizumab in combination with chemotherapy, followed by camrelizumab alone after 4-6 cycles of combination in participants with medically inoperable stage I or IIA non-small cell lung cancer (NSCLC). The primary objective of this pilot study is to determine the Camrelizumab plus chemotherapy improves progression-free survival (PFS) . All the efficacy and safety are assessed by investigator : 1) response rate (ORR), 2) disease control rate (DCR); 3) overall survival (OS), 4) PFS rate of 1-year, 2-year, and 5-year; and 5) OS rate of 1-year, 2-year, and 5-year.
Explore objective is potential biomarker associated with efficacy.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Changli Wang, PhD
- Numéro de téléphone: 6417 86-22-23340123
- E-mail: wangchangli@medmail.com.cn
Sauvegarde des contacts de l'étude
- Nom: Lianming Zhang, PhD
- Numéro de téléphone: 6417 86-22-23340123
Lieux d'étude
-
-
-
Tianjin, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute and Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients aged ≥18 years, male and female are not limited;
- Patients with ECOG score of 0-1;
- Life expectancy ≥12 weeks;
- Patients must have histologically- or cytologically-documented NSCLC (according to 2015 WHO Classification);
- Patients with stage I - IIA (T1-T2bN0M0, tumor size ≤ 50mm) confirmed by radiographic;and medical inoperable, unable to undergo thoracic surgery, or refusing to surgery (according to the eighth edition of TNM staging);
- Patients with measurable target lesions according to the RECIST 1.1 standard;
- Patients have not received prior treatment for their NSCLC, including radiotherapy, chemotherapy, surgery and target drugs;
- Can provide tumor tissue;
- Adequate organ and marrow function;
- Fertile female were required to have a serum or urine pregnancy test within 72 hours before the start dose of study medication and the result has been negative;If female of childbearing potential, is willing to use adequate contraception for the course of the study through 90 days after the last dose of study medication; if male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 90 days after the last dose of study medication;
- Provision of signed ICF.
Exclusion Criteria:
- Known any distance metastases;
- Patients with known EGFR gene mutation or ALK fusion mutation;
- Patients with any active autoimmune disease or history of autoimmune disease;
- Patients with innate or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or co-infection with hepatitis B and hepatitis C;
- Subjects requiring systemic treatment with corticosteroids (> 10 mg / day of prednisone or its equivalent) or other immunosuppressants within 14 days prior to the first administration;
- Patient must not have received a live, attenuated vaccine within 4 weeks prior to the first administration;
- Any therapy for NSCLC treatment;
- Patients with other malignant tumors in the past 5 years;
- Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiologic pneumonia, drug-induced pneumonia and active pneumonia confirmed by imaging;
- Patients with cardiac insufficiency;
- Routine urine test indicated that urine protein was >= (+ +), or 24-hour urine protein was >= 1g, or severe liver and kidney dysfunction;
- Patients with severe infection or fever of unknown origin >38.5 ℃ within 4 weeks prior to the first administration;
- Patients with known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures;
- Known allergies, hypersensitivity, or intolerance to camrelizumab or its excipients or to pemetrexed or to nab-paclitaxel;
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results,or the patient is unlikely to comply with study procedures, restrictions, and requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Camrelizumab combined with chemotherapy
Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy. Interventions: Biological: Camrelizumab |
chimiothérapie
Autres noms:
PD-1
Autres noms:
chemotherapy
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Progression-free Survival (PFS)
Délai: up to approximately 3 years
|
PFS is determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
|
up to approximately 3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall Survival (OS)
Délai: up to approximately 5 years
|
OS is defined as the first date of treatment to date of death from any causes.
|
up to approximately 5 years
|
Objective response rate (ORR)
Délai: up to approximately 1 years
|
ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 by investigator.
|
up to approximately 1 years
|
Disease Control Rate (DCR)
Délai: up to approximately 3 years
|
DCR is defined as the percentage of patients who have achieved complete response and partial response per RECIST 1.1 by investigator..
|
up to approximately 3 years
|
Adverse Events (AEs)
Délai: up to 18 months
|
The number of participants experiencing an AE will be assessed.
|
up to 18 months
|
PFS à 12 mois (PFS12)
Délai: jusqu'à 12 mois maximum
|
La SSP sera calculée à l'aide des méthodes de limite de produit de Kaplan-Meier.
|
jusqu'à 12 mois maximum
|
PFS at 24 months (PFS24)
Délai: up to maximum 24 months
|
PFS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 24 months
|
PFS at 5 years
Délai: up to maximum 5 years
|
PFS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 5 years
|
SG à 12 mois (SG12)
Délai: jusqu'à 12 mois maximum
|
La SG sera calculée à l'aide des méthodes de limite de produit de Kaplan-Meier.
|
jusqu'à 12 mois maximum
|
SG à 24 mois (OS24)
Délai: jusqu'à 24 mois maximum
|
La SG sera calculée à l'aide des méthodes de limite de produit de Kaplan-Meier.
|
jusqu'à 24 mois maximum
|
OS at 5 years
Délai: up to maximum 5 years
|
OS will be calculated using Kaplan-Meier product limit methods.
|
up to maximum 5 years
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs pulmonaires
- Carcinome pulmonaire non à petites cellules
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Agents antinéoplasiques phytogéniques
- Antagonistes de l'acide folique
- Paclitaxel
- Paclitaxel lié à l'albumine
- Pémétrexed
Autres numéros d'identification d'étude
- MA-NSCLC-II-007
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Pémétrexed
-
Rongjie TaoNational Natural Science Foundation of ChinaInconnueMétastases cérébralesChine
-
CanBas Co. Ltd.ComplétéTumeurs solides | Mésothéliome pleural malinÉtats-Unis
-
Northwestern UniversityNational Cancer Institute (NCI)InconnueLymphome | Tumeurs du cerveau et du système nerveux central | Cancer métastatiqueÉtats-Unis
-
PfizerRésiliéCarcinome, poumon non à petites cellulesÉtats-Unis, Allemagne, Italie
-
Ain Shams UniversityInconnue
-
Threshold PharmaceuticalsEMD SeronoRésiliéCancer du poumon non à petites cellulesÉtats-Unis, Allemagne, Espagne, Pologne, Grèce, Tchéquie, Hongrie, Italie, Roumanie, Fédération Russe
-
The First Affiliated Hospital with Nanjing Medical...InconnueCancer du poumon non à petites cellules non épidermoïde
-
PfizerComplétéNSCLC (cancer du poumon non à petites cellules)Hong Kong, Chine, Taïwan, Malaisie, Thaïlande
-
Incyte CorporationMirati Therapeutics Inc.RecrutementTumeurs solides avancéesÉtats-Unis, Canada, Espagne, Royaume-Uni, Italie
-
Spanish Lung Cancer GroupRésiliéCarcinome pulmonaire non à petites cellulesEspagne